<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02851797</url>
  </required_header>
  <id_info>
    <org_study_id>EPYDIS (DSC/14/2357/48)</org_study_id>
    <nct_id>NCT02851797</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy</brief_title>
  <official_title>Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italfarmaco</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Italfarmaco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      it is a randomised, double blind, parallel group, placebo controlled study. A total of 213
      male ambulant subjects will be randomised 2:1 (givinostat:placebo).

      Subjects will be stratified for their concomitant use of steroids in 4 strata:

        1. Deflazacort daily regimen

        2. Deflazacort intermittent regimen

        3. Other steroids daily regimen

        4. Other steroids intermittent regimen. The study duration is planned for 19 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Givinostat or placebo oral suspension (10 mg/mL) will be administered orally as 2 oral doses
      daily while the subject is in fed state, according to the child's weight.

      Study drug should be permanently stopped if any of the following occur:

        -  severe drug-related diarrhoea;

        -  any drug-related Serious Adverse Event;

        -  QTcF &gt;500 msec;

        -  platelets count ≤50 x 10^9/L.

        -  white blood cells ≤2.0 x 10^9/L

        -  hemoglobin ≤8.0 g/dL

      Study drug should be temporarily stopped if any of the following occur:

        -  moderate or severe diarrhoea.

        -  platelets count &lt;75 x 10^9/L but &gt;50 x 10^9/L (the treatment should be temporarily
           stopped and a platelets count has to be performed and re-tested until platelets will be
           normalized);

        -  white blood cell &lt;3.0 x 10^9/L but &gt;2.0 x 10^9/L (the treatment should be temporarily
           stopped and white blood cells have to be measured by 1 week and re-tested until white
           blood cells will be normalized);

        -  hemoglobin &lt;10.0 g/dL but &gt; 8.0 g/dL (the treatment should be temporarily stopped and
           hemoglobin has to be measured by 1 week and re-tested until hemoglobin will be
           normalized);

        -  Triglycerides &gt;300 mg/dL (3.42 mmol/L) in fasting condition (the treatment should be
           temporarily stopped and triglycerides has to be measured every 2 weeks until
           triglycerides return to levels below 300mg/dL (3.42 mmol/L)

      In case the study drug was temporarily stopped, the study drug can be resumed at a level 20%
      smaller than the one at which the Adverse Event leading to temporary stop occurred, once
      platelets and/or white blood cell and/or hemoglobin are normalized and/or triglycerides
      return to levels below 300 mg/dL (3.42 mmol/L) or diarrhoea is mild.

      In addition, in case a subject will have a consistent (e.g., at least 2 consecutive
      evaluations) platelets count ≤150 x 10^9/L and not meeting the stopping criteria for
      platelets, the Investigator will have to reduce the dose by 20% of the current dose.

      Only one dose reduction is allowed during the treatment period.

      Two interim analyses are planned and will be conducted by the IDMC in order to ensure study
      integrity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean change in 4 standard stairs climb</measure>
    <time_frame>18 months</time_frame>
    <description>the primary endpoint is the mean change in 4 standard stairs climb test results before and after 18 months of treatment of givinostat versus placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other functional test as 6MWT</measure>
    <time_frame>18 months</time_frame>
    <description>the mean change in 6MWT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to rise from floor</measure>
    <time_frame>18 months</time_frame>
    <description>the mean change in time to rise from floor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Spetroscopy</measure>
    <time_frame>18 months</time_frame>
    <description>the mean change in fat fraction of vastus lateralis muscles at MRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>North Star Ambulatory Assessment</measure>
    <time_frame>18 months</time_frame>
    <description>the mean change in North Star Ambulatory Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength evaluated by knee extension, elbow flexion</measure>
    <time_frame>18 months</time_frame>
    <description>the mean change of muscle strength evaluated by knee extension, elbow flexion as measured by hand-held myometry (HHM)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">213</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>givinostat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Givinostat oral suspension (10 mg/mL) twice daily in a fed state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral suspension (10 mg/mL) twice daily in a fed state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>givinostat</intervention_name>
    <description>suspension of givinostat (10 mg/mL)</description>
    <arm_group_label>givinostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>suspension manufactured to mimic givinostat</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Are an ambulant male aged ≥6 years at randomisation with DMD characteristic clinical
             symptoms or signs (e.g., proximal muscle weakness, Gowers' maneuver, elevated serum
             creatinine kinase level) already present at screening;

          2. Have DMD diagnosis confirmed by genetic testing;

          3. Are able to give informed assent and/or consent in writing signed by the subject
             and/or parent/legal guardian (according to local regulations);

          4. Are able to complete 2 Four Stairs Climb test (4SC) screening assessments; the results
             of these tests must be within ±1 second of each other;

          5. Have the mean of 2 screening 4SC assessments ≤8 seconds;

          6. Have time to rise from floor between ≥3 and &lt;10 seconds at screening

          7. Have manual muscle testing (MMT) of quadriceps at screening Grade ≥- 3;

          8. Have used systemic corticosteroids for a minimum of 6 months immediately prior to the
             start of study treatment, with no significant change in corticosteroids type or dosage
             or dosing regimen (excluding changes related to body weight change) for a minimum of 6
             months immediately prior to start of study treatment and a reasonable expectation that
             dosage and dosing regimen will not change significantly for the duration of the study.

          9. Subjects must be willing to use adequate contraception.

        Exclusion Criteria:

          1. Have exposure to another investigational drug within 3 months prior to the start of
             study treatment;

          2. Have exposure to idebenone within 3 months prior to the start of study treatment;

          3. Have exposure to any dystrophin restoration product (e.g., Ataluren, Exon skipping)
             within 6 months prior to the start of study treatment;

          4. Use of any pharmacologic treatment, other than corticosteroids, that might have had an
             effect on muscle strength or function within 3 months prior to the start of study
             treatment (e.g., growth hormone); Vitamin D, calcium, and any other supplements will
             be allowed as long as their intake has been stable for 3 months prior to the start of
             study treatment; Testosterone will also be allowed if it is used as a replacement
             therapy for the treatment of delayed puberty, and testosterone dose and regimen have
             been stable for at least 6 months and circulating testosterone levels are within the
             normal ranges for the subject's age;

          5. Have surgery that might have an effect on muscle strength or function within 3 months
             before study entry or planned surgery at any time during the study;

          6. Ankle joint contractures due to a fixed loss of ≥10 degrees of dorsiflexion from
             plantagrade assuming a normal range of dorsiflexion of 20 degree;

          7. Change in contracture treatment such as serial casting, contracture control devices,
             night splints, stretching exercises (passive, active, self) within 3 months prior to
             enrollment, or expected need for such intervention during the study;

          8. Have presence of other clinically significant disease, which, in the Investigator's
             opinion, could adversely affect the safety of the subject, making it unlikely that the
             course of treatment or follow-up would be completed, or could impair the assessment of
             study results;

          9. Have a diagnosis of other uncontrolled neurological diseases or presence of relevant
             uncontrolled somatic disorders that are not related to DMD;

         10. Have platelets count at screening &lt; Lower Limit of Normal (LLN);

         11. Have symptomatic cardiomyopathy or heart failure (New York Heart Association Class III
             or IV) or left ventricular ejection fraction &lt;50% at screening;

         12. Have a current or history of liver disease or impairment;

         13. Have inadequate renal function, as defined by serum Cystatin C &gt;2 x the upper limit of
             normal (ULN);

         14. Have Triglycerides &gt; 300 mg/dL (3.42 mmol/L) in fasting condition at screening visit;

         15. Have a baseline QTcF &gt;450 msec, or history of additional risk factors for torsades de
             pointes (e.g., heart failure, hypokalemia, or family history of long QT syndrome);

         16. Have a psychiatric illness/social situations rendering the potential subject unable to
             understand and comply with the muscle function tests and/or with the study protocol
             procedures;

         17. Have any known allergic reaction to givinostat or any of its excipients.

         18. Have any hypersensitivity to the components of study medication;

         19. Have a sorbitol intolerance or sorbitol malabsorption, or have the hereditary form of
             fructose intolerance.

         20. Have contraindications to MRI or MRS (e.g., claustrophobia, metal implants, or seizure
             disorder).

        At the discretion of the Investigator, subjects not meeting inclusion/exclusion criteria
        may be re-screened twice with an interval of at least 3 months between assessments.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Reference Study ID Number EPYDIS (DSC/14/2357/48)</last_name>
    <phone>+39 026443</phone>
    <phone_ext>2524</phone_ext>
    <email>patientadvocacy@italfarmaco.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neuromuscular Research Center UC Davis Department of Physical Medicine and Rehabilitation</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Goude</last_name>
      <email>emgoude@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Craig McDonald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>David Geffen School of Medicine - UCLA Neurology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital center - UCSD Department of Neuroscience</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Reit</last_name>
      <email>jreit@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Chamindra Konersman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center - Division Neurology</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikki Palmer</last_name>
      <email>VPalmer@connecticutchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Gyula Acsadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Child Health Research Institute - Department of Pediatrics</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Gee</last_name>
      <email>geekim@peds.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Barry Byrne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Rizzo, MD</last_name>
      <email>Virginia.Rizzo@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Richard Finkel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Rare Disease Research, LLC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcial Almaraz</last_name>
      <email>marcial.almaraz@rarediseasesresearch.com</email>
    </contact>
    <investigator>
      <last_name>Han Phan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Children's Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corey McDaniel</last_name>
      <email>corey-mcdaniel@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Katherine Mathews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University - University Pediatrics - Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota - Department of Neurology</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Vollbrecht</last_name>
      <email>vollb007@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Georgios Manousakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St Louis - Department of Neurology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyssa Sonsoucie</last_name>
      <email>amsonsoucie@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Craig Zaidman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shriners Hospitals for Children</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassandra Black</last_name>
      <email>ceb@shcc.org</email>
    </contact>
    <investigator>
      <last_name>Erika Finanger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia Colket Translational Research Building</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khrystine Ford</last_name>
      <phone>267-425-0158</phone>
      <email>fordka@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>John Brandsema, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Childrens Hospital of Richmond at Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn O'Hara, MD</last_name>
      <email>kathryn.ohara@vcuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Amy Harper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven, Neuromuscular Reference Centre, Child Neurology</name>
      <address>
        <city>Leuven</city>
        <zip>03000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Goemans, MD</last_name>
      <email>nathalie.goemans@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Nathalie Goemans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de La Citadelle, Centre de Référence des Maladies Neuromuscolaires (CRMN)</name>
      <address>
        <city>Liege</city>
        <zip>04000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Servais, MD</last_name>
      <email>l.servais@institut-myologie.org</email>
    </contact>
    <investigator>
      <last_name>Laurent Servais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kinsmen Research Centre - Alberta Children's Hospital - Alberta Health Services</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Mah, MD</last_name>
      <email>Jean.Mah@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Jean Mah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of British Columbia, Children's and Womens Health Centre of BC Branch</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Selby, MD</last_name>
      <email>kselby@cw.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Kathryn Selby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holland Bloorview Kids Rehabilitation Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura McAdam</last_name>
      <email>lmcadam@hollandbloorview.ca</email>
    </contact>
    <investigator>
      <last_name>Laura McAdam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hotel-Dieu - Hopital Nord Laennec, rez-de-chausse haut ail Ouest</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann Pereon, MD</last_name>
      <email>yann.pereon@univ-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Yann Pereon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Armand Trousseau I-Motion, Plateforme d'essais cliniques pédiatriques</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Odile Boespflug-Tanguy, MD</last_name>
      <email>odile.boespflug-tanguy@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Odile Boespflug-Tanguy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen - Kinder und Jugendmedizin Neuropadiatrie</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Schara, MD</last_name>
      <email>ulrike.schara@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Ulrike Schara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik un Policlinik fur Kinder und Jugendmedizin - Universitatsklinikum Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessika Johannssen, MD</last_name>
      <email>j.johannsen@uke.de</email>
    </contact>
    <investigator>
      <last_name>Jessika Johannssen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Uniersitat Munchen - Campus Innenstadt</name>
      <address>
        <city>Munchen</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid Blaschek, MD</last_name>
      <email>Astrid.Blaschek@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Muller-Felber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Neurology - Schneider Children's Medical Center of Israel Kaplan, 14</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>4920235</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liraz Kraus, SC</last_name>
      <phone>972-3-9253398</phone>
      <email>lirazkr@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Lee Bareket-Kisler, SC</last_name>
      <phone>972-3-9253398</phone>
      <email>leek1@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Yoram Nevo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto G.Gaslini, U.O.S.D. Centro Traslazionale di Miologia e Patologie Neurodegenerative</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Bruno, MD</last_name>
      <email>claudiobruno@ospedale-gaslini.ge.it</email>
    </contact>
    <investigator>
      <last_name>Claudio Bruno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico G. Martino, U.O.C. Neurologia e Malattie Neuromuscolari</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Vita, MD</last_name>
      <email>vitag@unime.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Vita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, UOS di Neurologia Pediatrica</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giacomo Comi, MD</last_name>
      <email>giacomo.comi@unimi.it</email>
    </contact>
    <investigator>
      <last_name>Giacomo Comi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Neurologico Carlo Besta</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riccardo Masson, MD</last_name>
      <email>Riccardo.Masson@istituto-besta.it</email>
    </contact>
    <investigator>
      <last_name>Riccardo Masson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Clinico NeMO Fondazione Serena ONLUS Area SUD</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valeria Sansone, MD</last_name>
      <phone>0291433734</phone>
      <email>valesans65@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Valeria Sansone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambin Gesù, Malattie Neuromuscolari e Neurodegenerative</name>
      <address>
        <city>Roma</city>
        <zip>00146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Bertini, MD</last_name>
      <email>enricosilvio.bertini@opbg.net</email>
    </contact>
    <investigator>
      <last_name>Enrico Bertini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario &quot;A.Gemelli&quot;, UOC Neuropsichiatria Infantile</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenio Mercuri, MD</last_name>
      <email>eumercuri@gmail.com</email>
    </contact>
    <contact_backup>
      <email>eugeniomaria.mercuri@policlinicogemelli.it</email>
    </contact_backup>
    <investigator>
      <last_name>Eugenio Mercuri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center LUMC</name>
      <address>
        <city>Leiden</city>
        <zip>ZH 2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Mosselman, MD</last_name>
      <email>Duchenne@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>Erik Niks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imelda de Groot, MD</last_name>
      <email>Imelda.deGroot@radboudumc.nl</email>
    </contact>
    <investigator>
      <last_name>Imelda de Groot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinic of Neurology and Psychiatry for Children and Youth - Neurology Department Dr. Subotic 6a,</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Kosac, SC</last_name>
      <phone>00381 11 265 8355</phone>
      <email>kosacana@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vedrana Milic Rasic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu - Neuromuscular Pathology Unit</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Nascimento, MD</last_name>
      <email>anascimento@sjdhospitalbarcelona.org</email>
    </contact>
    <investigator>
      <last_name>Andres Nascimento, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Materno-Infantil - Passeig de la Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francina Munell, MD</last_name>
      <email>francina.munell@vhir.org</email>
    </contact>
    <investigator>
      <last_name>Francina Munell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Javier Molina Ortega, ND</last_name>
      <phone>+34 669 393637</phone>
      <email>f.molina@fyamedical.com</email>
    </contact>
    <investigator>
      <last_name>Marcos Madruga Garrido, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politécnic de la Fe - Servicio Neurologia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Jesus Vilchez, MD</last_name>
      <email>vilchez_jje@gva.es</email>
    </contact>
    <investigator>
      <last_name>Juan Jesus Vilchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's Hospital NHS Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Ismail</last_name>
      <email>nadia.ismail@alderhey.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Stefan Spinty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCL Great Ormond Street Institute of Child Health, Dubowitz Neuromuscular Centre and MRC Centre for NMD</name>
      <address>
        <city>London</city>
        <zip>EC1N 1EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariacristina Scoto, MD</last_name>
      <email>m.scoto@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Mariacristina Scoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The John Walton Muscular Dystrophy Research Centre - Freeman Hospital - Newcastle University - Institute of Genetic Medicine</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 3BZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Straub, MD</last_name>
      <email>volker.straub@newcastle.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Michaela Guglieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Robert Jones and Agnes Hunt Orthopaedic Hospital - NHS Foundation Trust</name>
      <address>
        <city>Oswestry</city>
        <zip>SY 10 7AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Turner, MD</last_name>
      <email>Sarah.Turner2@rjah.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Tracey Willis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 27, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

